Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) FCF Margin: 2020-2025

Historic FCF Margin for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to 24.78%.

  • Xeris Biopharma Holdings' FCF Margin rose 4008.00% to 24.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.97%, marking a year-over-year increase of 2077.00%. This contributed to the annual value of -18.21% for FY2024, which is 1048.00% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' FCF Margin is 24.78%, which was up 9,640.65% from 0.25% recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' FCF Margin registered a high of 24.78% during Q3 2025, and its lowest value of -292.32% during Q1 2021.
  • Moreover, its 3-year median value for FCF Margin was -16.69% (2025), whereas its average is -18.50%.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 14,471bps in 2022, then slumped by 1,354bps in 2024.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' FCF Margin stood at -135.69% in 2021, then soared by 8,706bps to -48.63% in 2022, then spiked by 6,546bps to 16.83% in 2023, then plummeted by 1,354bps to 3.29% in 2024, then surged by 4,008bps to 24.78% in 2025.
  • Its last three reported values are 24.78% in Q3 2025, 0.25% for Q2 2025, and -16.69% during Q1 2025.